Gal3st4 Blocking Peptide, Blocking Peptides
- Known as:
- Gal3st4 Blocking Peptide, Blocking Peptides
- Catalog number:
- 33R-8096
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- Gal3st4 Blocking Peptide Peptides
Related genes to: Gal3st4 Blocking Peptide, Blocking Peptides
- Gene:
- GAL3ST4 NIH gene
- Name:
- galactose-3-O-sulfotransferase 4
- Previous symbol:
- -
- Synonyms:
- FLJ12116
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-23
- Date modifiied:
- 2014-11-18
Related products to: Gal3st4 Blocking Peptide, Blocking Peptides
Related articles to: Gal3st4 Blocking Peptide, Blocking Peptides
- Pectus excavatum (PE) is the most common congenital chest wall deformity, affecting approximately 1 in 400 live births. Although familial clustering supports a genetic contribution, the molecular basis of PE remains poorly defined. This systematic review synthesizes existing evidence on genetic variants associated with PE to guide future genome-wide association studies (GWAS) and Mendelian randomization (MR) analyses. - Source: PubMed
Publication date: 2026/01/22
Ranjan RedoyImtiaz NafizWaterhouse BenjaminPaul IanBrunswicker AnnemarieDunning Joel - Many cancers upregulate the expression of sialic acid-containing glycans. These oligosaccharides engage inhibitory sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on immune cells, allowing cancer cells to evade immune surveillance. The genetic mechanisms underlying this process remain poorly defined. In this study, we performed gain-of-function CRISPR activation (CRISPRa) screens to define genetic pathways that regulate expression of Siglec-binding glycans. We show that Siglec ligand expression is controlled through genetic competition between genes that catalyze α2-3 sialylation and GlcNAcylation of galactose residues. Cancer glycome remodeling is also aided by the overexpression of "professional ligands" that facilitate Siglec-glycan binding. Notably, we also find that expression of the CD24 gene is genetically dispensable for cell surface binding of the inhibitory receptor Siglec-10. Finally, we identify the sulfotransferase enzyme GAL3ST4 as a potential driver of immune evasion in glioma cells. Our study provides a unique genomic atlas of cancer-associated glycosylation and identifies immediately actionable targets for cancer immunotherapy. - Source: PubMed
Publication date: 2026/01/28
Daly JohnPiatnitca LidiaAl-Seragi MohammedKrishnamoorthy VigneshWisnovsky Simon - The aim of this study is to investigate the pathophysiology of cataract by analyzing signaling pathways in three sample types obtained from four different lens groups: age-related (ARC), diabetic (DC), post-vitrectomy cataract (PVC) and clear control lenses. - Source: PubMed
Publication date: 2025/11/21
Karakosta ChristinaSamiotaki MartinaBisoukis AnastasiosBougioukas Konstantinos IPanayotou GeorgeKyriakidou NantiezntaMoschou KonstantinosMoschos Marilita M - Glioma-associated macrophages (GAMs) originate from intracranially resident microglia and myeloid-derived macrophages. In the glioma microenvironment, these two types of macrophages tend to adopt a specialized activation state known as type 2 or M2 macrophages and play crucial roles in the progression of glioma. - Source: PubMed
Publication date: 2025/06/06
Wang XisenWang XuyaChen LeiDing HaozheFan JikangLiang JianshenZhang YuLi YimingZhang YimingYu ShengpingZhang ChenLi YaohuaLi TaoYang Xuejun - Tumor microenvironment (TME), particularly immune cell infiltration, programmed cell death (PCD) and stress, has increasingly become a focal point in colorectal cancer (CRC) treatment. Uncovering the intricate crosstalk between these factors can enhance our understanding of CRC, guide therapeutic strategies, and improve patient prognosis. - Source: PubMed
Publication date: 2025/01/28
Liu HaoZhang ChuhanPeng SanfeiYin YuhanXu YishiWu SihanWang LipingFu Yang